Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05270057 |
|
Recruitment Status :
Not yet recruiting
First Posted : March 8, 2022
Last Update Posted : June 14, 2022
|
Sponsor:
Medical College of Wisconsin
Information provided by (Responsible Party):
Mehdi Hamadani, Medical College of Wisconsin
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), and rituximab (DA-EPOCH-R) for patients with previously untreated aggressive B-cell lymphoid malignancies.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| B-cell Lymphoma Burkitt Lymphoma | Drug: Etoposide Drug: Doxorubicin Drug: Cyclophosphamide Drug: Rituximab Drug: Vincristine Drug: Prednisone Drug: Loncastuximab Tesirine 0.075 mg/kg by IV Drug: Loncastuximab tesirine 0.12 mg/kg by IV Drug: Loncastuximab tesirine 0.15 mg/kg by IV | Phase 1 |
This is a multicenter phase 1, open-label trial that will evaluate the safety and tolerability of loncastuximab tesirine in combination with DA-EPOCH-R.
Phase 1a will involve a standard 3+3 dose escalation design to find the maximum tolerated dose (MTD) and/or recommended dose for expansion. The MTD will be determined based on the results of the safety evaluation. No intra-patient dose escalation is allowed.
Phase 1b will involve a cohort expansion at the dose level determined to be the recommended phase 2 dose.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 33 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Intervention Model Description: | Phase 1a will involve a standard 3+3 dose escalation design to find the maximal tolerated dose (MTD) and/or recommended dose for expansion. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies |
| Estimated Study Start Date : | August 2022 |
| Estimated Primary Completion Date : | May 2027 |
| Estimated Study Completion Date : | May 2028 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Loncastuximab tesirine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Loncastuximab Tesirine Dose Escalation 0.075 mg/kg by IV.
The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
|
Drug: Etoposide
Dose level -2=50 mg/m^2; dose level -1=50 mg/m^2; dose level 1=50 mg/m^2; dose level 2=60 mg/m^2; dose level 3=72 mg/m^2; dose level 4=86.4 mg/m^2; dose level 5=103.7 mg/m^2; dose level 6=124.4 mg/m^2; dose level 7=149.3 mg/m^2
Other Names:
Drug: Doxorubicin Dose level -2=10 mg/m^2; dose level -1; dose level -1=10 mg/m^2; dose level 1=10 mg/m^2; dose level 2=12 mg/m^2; dose level 3=14.4 mg/m^17.3 mg/m^2; dose level 4=17.3 mg/m^2; dose level 5=20.7 mg/m^2; dose level 6=24.8 mg/m^2; dose level 7=29.8 mg/m^2.
Other Names:
Drug: Cyclophosphamide Dose level -2=480 mg/m^2; dose -1=600 mg/m^2; dose level 1=750 mg/m^2; level 2=900 mg/m^2; level 3=1080 mg/m^2; level 4=1296 mg/m^2; level 5=1555 mg/m^2; level 6=1866 mg/m^2; level 7=2239 mg/m^2.
Other Names:
Drug: Rituximab Level -2 through level 7: 375 mg/m^2
Other Names:
Drug: Vincristine Level -2 through level 7: 0.4 mg/m^2/day
Other Names:
Drug: Prednisone Level -2 through level 7: 60 mg/m^2/twice daily (BID)
Other Names:
Drug: Loncastuximab Tesirine 0.075 mg/kg by IV Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
|
|
Experimental: Loncastuximab Tesirine Dose Escalation 0.12 mg/kg by IV.
The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
|
Drug: Etoposide
Dose level -2=50 mg/m^2; dose level -1=50 mg/m^2; dose level 1=50 mg/m^2; dose level 2=60 mg/m^2; dose level 3=72 mg/m^2; dose level 4=86.4 mg/m^2; dose level 5=103.7 mg/m^2; dose level 6=124.4 mg/m^2; dose level 7=149.3 mg/m^2
Other Names:
Drug: Doxorubicin Dose level -2=10 mg/m^2; dose level -1; dose level -1=10 mg/m^2; dose level 1=10 mg/m^2; dose level 2=12 mg/m^2; dose level 3=14.4 mg/m^17.3 mg/m^2; dose level 4=17.3 mg/m^2; dose level 5=20.7 mg/m^2; dose level 6=24.8 mg/m^2; dose level 7=29.8 mg/m^2.
Other Names:
Drug: Cyclophosphamide Dose level -2=480 mg/m^2; dose -1=600 mg/m^2; dose level 1=750 mg/m^2; level 2=900 mg/m^2; level 3=1080 mg/m^2; level 4=1296 mg/m^2; level 5=1555 mg/m^2; level 6=1866 mg/m^2; level 7=2239 mg/m^2.
Other Names:
Drug: Rituximab Level -2 through level 7: 375 mg/m^2
Other Names:
Drug: Vincristine Level -2 through level 7: 0.4 mg/m^2/day
Other Names:
Drug: Prednisone Level -2 through level 7: 60 mg/m^2/twice daily (BID)
Other Names:
Drug: Loncastuximab tesirine 0.12 mg/kg by IV Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
|
|
Experimental: Loncastuximab Tesirine Dose Escalation 0.15 mg/kg by IV.
The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
|
Drug: Etoposide
Dose level -2=50 mg/m^2; dose level -1=50 mg/m^2; dose level 1=50 mg/m^2; dose level 2=60 mg/m^2; dose level 3=72 mg/m^2; dose level 4=86.4 mg/m^2; dose level 5=103.7 mg/m^2; dose level 6=124.4 mg/m^2; dose level 7=149.3 mg/m^2
Other Names:
Drug: Doxorubicin Dose level -2=10 mg/m^2; dose level -1; dose level -1=10 mg/m^2; dose level 1=10 mg/m^2; dose level 2=12 mg/m^2; dose level 3=14.4 mg/m^17.3 mg/m^2; dose level 4=17.3 mg/m^2; dose level 5=20.7 mg/m^2; dose level 6=24.8 mg/m^2; dose level 7=29.8 mg/m^2.
Other Names:
Drug: Cyclophosphamide Dose level -2=480 mg/m^2; dose -1=600 mg/m^2; dose level 1=750 mg/m^2; level 2=900 mg/m^2; level 3=1080 mg/m^2; level 4=1296 mg/m^2; level 5=1555 mg/m^2; level 6=1866 mg/m^2; level 7=2239 mg/m^2.
Other Names:
Drug: Rituximab Level -2 through level 7: 375 mg/m^2
Other Names:
Drug: Vincristine Level -2 through level 7: 0.4 mg/m^2/day
Other Names:
Drug: Prednisone Level -2 through level 7: 60 mg/m^2/twice daily (BID)
Other Names:
Drug: Loncastuximab tesirine 0.15 mg/kg by IV Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
|
|
Experimental: Loncastuximab Tesirine Dose Escalation Maximum Tolerated Dose
The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD. This dose will be added to this record when it is determined.
|
Drug: Etoposide
Dose level -2=50 mg/m^2; dose level -1=50 mg/m^2; dose level 1=50 mg/m^2; dose level 2=60 mg/m^2; dose level 3=72 mg/m^2; dose level 4=86.4 mg/m^2; dose level 5=103.7 mg/m^2; dose level 6=124.4 mg/m^2; dose level 7=149.3 mg/m^2
Other Names:
Drug: Doxorubicin Dose level -2=10 mg/m^2; dose level -1; dose level -1=10 mg/m^2; dose level 1=10 mg/m^2; dose level 2=12 mg/m^2; dose level 3=14.4 mg/m^17.3 mg/m^2; dose level 4=17.3 mg/m^2; dose level 5=20.7 mg/m^2; dose level 6=24.8 mg/m^2; dose level 7=29.8 mg/m^2.
Other Names:
Drug: Cyclophosphamide Dose level -2=480 mg/m^2; dose -1=600 mg/m^2; dose level 1=750 mg/m^2; level 2=900 mg/m^2; level 3=1080 mg/m^2; level 4=1296 mg/m^2; level 5=1555 mg/m^2; level 6=1866 mg/m^2; level 7=2239 mg/m^2.
Other Names:
Drug: Rituximab Level -2 through level 7: 375 mg/m^2
Other Names:
Drug: Vincristine Level -2 through level 7: 0.4 mg/m^2/day
Other Names:
Drug: Prednisone Level -2 through level 7: 60 mg/m^2/twice daily (BID)
Other Names:
Drug: Loncastuximab Tesirine 0.075 mg/kg by IV Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
Drug: Loncastuximab tesirine 0.12 mg/kg by IV Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
Drug: Loncastuximab tesirine 0.15 mg/kg by IV Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
|
|
Experimental: Dose Expansion Phase
Subjects will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase. This dose will be added to this record when it is determined.
|
Drug: Etoposide
Dose level -2=50 mg/m^2; dose level -1=50 mg/m^2; dose level 1=50 mg/m^2; dose level 2=60 mg/m^2; dose level 3=72 mg/m^2; dose level 4=86.4 mg/m^2; dose level 5=103.7 mg/m^2; dose level 6=124.4 mg/m^2; dose level 7=149.3 mg/m^2
Other Names:
Drug: Doxorubicin Dose level -2=10 mg/m^2; dose level -1; dose level -1=10 mg/m^2; dose level 1=10 mg/m^2; dose level 2=12 mg/m^2; dose level 3=14.4 mg/m^17.3 mg/m^2; dose level 4=17.3 mg/m^2; dose level 5=20.7 mg/m^2; dose level 6=24.8 mg/m^2; dose level 7=29.8 mg/m^2.
Other Names:
Drug: Cyclophosphamide Dose level -2=480 mg/m^2; dose -1=600 mg/m^2; dose level 1=750 mg/m^2; level 2=900 mg/m^2; level 3=1080 mg/m^2; level 4=1296 mg/m^2; level 5=1555 mg/m^2; level 6=1866 mg/m^2; level 7=2239 mg/m^2.
Other Names:
Drug: Rituximab Level -2 through level 7: 375 mg/m^2
Other Names:
Drug: Vincristine Level -2 through level 7: 0.4 mg/m^2/day
Other Names:
Drug: Prednisone Level -2 through level 7: 60 mg/m^2/twice daily (BID)
Other Names:
Drug: Loncastuximab Tesirine 0.075 mg/kg by IV Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
Drug: Loncastuximab tesirine 0.12 mg/kg by IV Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
Drug: Loncastuximab tesirine 0.15 mg/kg by IV Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
Other Names:
|
Primary Outcome Measures :
- The maximum tolerated dose (MTD). [ Time Frame: Up to 21 days (one cycle) for each dosing cohort. ]MTD is defined as the highest dose level where zero of the first three patients treated or ≤1 of the first six patients treated had a dose-limiting toxicity (DLT) during cycle 1 of phase 1a.
- The number of dose-limiting toxicities (dose-escalation phase only). [ Time Frame: Up to 21 days (one cycle). ]A dose-limiting toxicity is defined as any of the following within 21 days after administration of the first dose of loncastuximab tesirine in phase 1a part 1a only (except any toxicity clearly due to disease or other causes): adverse events and lab data, using Common Terminology Criteria for Adverse Events (CTCAE) v.5.0.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥ 18 years.
- Adult patients with B-cell lymphoma, specifically one of the following: high-grade B-cell lymphoma with MYC and B-cell lymphoma 2 (BCL2) and/or B cell lymphoma 6 (BCL6) rearrangements; high-grade B-cell lymphoma, not otherwise specified, primary mediastinal diffuse large B-cell lymphoma; Burkitt lymphoma; diffuse large B-cell lymphoma with MYC rearrangement; or Cluster of Differentiation 19 (CD19) -positive plasmablastic lymphoma.
- Patients must not have received prior multiagent chemotherapy for their lymphoma. Limited palliative radiation is allowed. Corticosteroid therapy in symptomatic patients will be permitted and does not require a washout period. Prephase treatment with cyclophosphamide and corticosteroids or vincristine and corticosteroids is allowed in symptomatic patients.
- Eastern Cooperative Oncology Group (ECOG) Performance Status criteria of 0-3 (see Appendix 1).
-
Adequate hematological function, defined as absolute neutrophil count (ANC) ≥1 × 103/μL and platelet count ≥50 x 10^3/μL.
- These requirements do not apply to patients with bone marrow involvement of lymphoma.
-
Adequate hepatic function: aspartate aminotransferase (AST) / alanine aminotransferase (ALT) / gamma-glutamyl transferase (GGT) ≤ 3 x institutional upper limit of normal (ULN) and bilirubin < 1.5 x ULN, unless due to hepatic involvement with lymphoma or Gilbert's syndrome.
- Exceptions can be granted from principal investigator for primarily indirect bilirubinemia if due to recent transfusion and/or hemolysis.
- estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73sqm.
- Left ventricular ejection fraction (LVEF) of ≥50%, assessed by echocardiography or cardiac multi-gated acquisition (MUGA) scan.
- Patients with marrow-only disease will be eligible.
- Patients rendered no evidence of disease via surgery will be eligible.
- Central nervous system (CNS) involvement is not considered contraindication for patients with Burkitt lymphoma.
- Known HIV-positive patients compliant with antiretroviral therapy and with undetectable viral loads will be permitted.
-
Pregnancy It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below.
- Female patients of childbearing potential must use a highly effective method of contraception during the entire study treatment period and through nine months after the last dose of loncastuximab tesirine.
- Male patients, even if surgically sterilized (i.e., status postvasectomy), with female partners who are of childbearing potential should use a condom when sexually active during the entire study treatment period and through six months after the last dose of loncastuximab tesirine.
- Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria:
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05270057
Contacts
| Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office | 866-680-0505 ext 8900 | cccto@mcw.edu |
Locations
| United States, Wisconsin | |
| Froedtert Hospital & the Medical College of Wisconsin | |
| Milwaukee, Wisconsin, United States, 53226 | |
| Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office 866-680-0505 ext 8900 cccto@mcw.edu | |
| Principal Investigator: Mehdi Hamadani, MD | |
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
| Principal Investigator: | Mehdi Hamadani, MD | Medical College of Wisconsin |
| Responsible Party: | Mehdi Hamadani, Professor, Medical College of Wisconsin |
| ClinicalTrials.gov Identifier: | NCT05270057 |
| Other Study ID Numbers: |
PRO00043132 |
| First Posted: | March 8, 2022 Key Record Dates |
| Last Update Posted: | June 14, 2022 |
| Last Verified: | June 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Burkitt Lymphoma Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, B-Cell Lymphoma, Non-Hodgkin Epstein-Barr Virus Infections Herpesviridae Infections DNA Virus Infections Virus Diseases Infections |
Tumor Virus Infections Prednisone Cyclophosphamide Rituximab Doxorubicin Liposomal doxorubicin Etoposide Vincristine Loncastuximab tesirine Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents |